Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial

Eli Lilly and Company -0.76% Pre

Eli Lilly and Company

LLY

922.50

928.84

-0.76%

+0.69% Pre

COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk NOVOb.CO said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s Tirzepatide in reducing body weight.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.